Production Method 1

501-36-0

861446-14-2

Reaction Conditions

1.1 Reagents: Pyridine ,  tert-Butyl methyl ether ;  2 h, rt
2.1 Catalysts: Silica Solvents: Methanol ,  Dichloromethane ;  62 h, rt

Reference

Synthesis of amphiphilic resveratrol lipoconjugates and evaluation of their anticancer activity towards neuroblastoma SH-SY5Y cell line

Chillemi, Rosa; et al, European Journal of Medicinal Chemistry, 2015, 96, 467-481

Production Method 2

861446-23-3

861446-14-2

Reaction Conditions

1.1 Reagents: Sodium pyrosulfite ,  Sodium sulfite Solvents: Tetrahydrofuran ,  Water

Reference

Synthesis of resveratrol and its analogs, phase-transfer catalyzed asymmetric glycolate aldol reactions, and total synthesis of 8,9-methylamido-geldanamycin

Liu, Jing, 2007, , 68(7),

Production Method 3

861446-23-3

861446-14-2

Reaction Conditions

1.1 Reagents: Sodium pyrosulfite ,  Sodium sulfite Solvents: Tetrahydrofuran ,  Water ;  9 h, rt

Reference

Synthesis of polyhydroxylated ester analogs of the stilbene resveratrol using decarbonylative Heck couplings

Andrus, Merritt B.; et al, Tetrahedron Letters, 2006, 47(32), 5811-5814

Production Method 4

501-36-0

861446-14-2

Reaction Conditions

1.1 Reagents: Triethylamine Solvents: Dichloromethane ;  12 h, rt

Reference

Synthesis and Biological Evaluation of Resveratrol Methoxy Derivatives

Fragopoulou, Elizabeth; et al, Molecules, 2023, 28(14),

Resveratrol 3,4’-Diacetate Raw materials

• Resveratrol
• 1-O-Levulinoyl Resveratrol Diacetate

Resveratrol 3,4’-Diacetate Preparation Products

• Resveratrol 3,4’-Diacetate (861446-14-2)

• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 3. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Recent Advances in Resveratrol 3,4’-Diacetate (CAS: 861446-14-2) Research: A Comprehensive Review

Resveratrol 3,4’-Diacetate (CAS: 861446-14-2), a chemically modified derivative of resveratrol, has garnered significant attention in recent years due to its enhanced bioavailability and potential therapeutic applications. This research briefing synthesizes the latest findings on this compound, focusing on its pharmacological properties, mechanisms of action, and clinical relevance. The growing body of evidence suggests that Resveratrol 3,4’-Diacetate may offer superior stability and efficacy compared to its parent compound, making it a promising candidate for further development in the pharmaceutical and nutraceutical industries.

Recent studies have elucidated the molecular mechanisms underlying the biological activities of Resveratrol 3,4’-Diacetate. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent anti-inflammatory and antioxidant effects by modulating the NF-κB and Nrf2 signaling pathways. The diacetate modification enhances cellular uptake, thereby improving its therapeutic potential in conditions such as cardiovascular diseases, neurodegenerative disorders, and cancer. These findings underscore the importance of structural optimization in maximizing the benefits of resveratrol-based therapeutics.

In addition to its pharmacological properties, Resveratrol 3,4’-Diacetate has shown promise in preclinical models of metabolic disorders. A recent investigation highlighted its ability to improve insulin sensitivity and reduce hepatic steatosis in obese mice, suggesting potential applications in managing type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The study, conducted by researchers at the University of California, utilized advanced metabolomics techniques to identify key metabolic pathways influenced by the compound, providing a foundation for future clinical trials.

The synthesis and scalability of Resveratrol 3,4’-Diacetate have also been areas of active research. A 2024 report in Organic Process Research & Development detailed an optimized synthetic route that improves yield and purity while reducing production costs. This advancement is critical for transitioning the compound from laboratory-scale research to large-scale pharmaceutical production. Furthermore, stability studies have confirmed that the diacetate derivative maintains its integrity under various storage conditions, addressing one of the major challenges associated with resveratrol formulations.

Despite these promising developments, challenges remain in the clinical translation of Resveratrol 3,4’-Diacetate. Current research gaps include the need for comprehensive toxicology studies and human clinical trials to establish safety and efficacy profiles. Collaborative efforts between academia and industry are essential to accelerate the development of this compound and unlock its full therapeutic potential. As the field progresses, Resveratrol 3,4’-Diacetate is poised to become a cornerstone in the next generation of bioactive compounds for health and disease management.

• 2628-16-2(4-Acetoxystyrene)
• 920489-98-1(3-Acetoxy-5-hydroxy Styrene)
• 5912-87-8(Acetylisoeugenol)
• 155222-48-3(3,5-Diacetoxy Styrene)
• 93-29-8(Isoeugenol acetate)
• 42206-94-0(Triacetylresveratrol)
• 71144-78-0((E)-3-Acetoxy-5-methoxystilbene)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)